Fingerprint
Dive into the research topics where Alona Zer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches
Revenko, D., Shirron, N., Shainer, R., Avitan-Hersh, E. & Zer, A., Mar 2026, In: Cancers. 18, 6, 1008.Research output: Contribution to journal › Review article › peer-review
Open Access -
Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World Study
Daher, S., Shalata, W., Shirron, N., Shentzer, T., Goshen-Lago, T., Biras, L., Moskovitz, M., Shamai, S., Urban, D., Gantz-Sorotsky, H., Lobachov, A., Dudnik, J., Cohen, A. Y., Yakobson, A., Zer, A. & Bar, J., May 2026, In: JTO Clinical and Research Reports. 7, 5, 100981.Research output: Contribution to journal › Article › peer-review
Open Access -
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
Saini, K. S., Koopman, M., Martins-Branco, D., Bossi, P., Braendegaard Winther, S., Brahmi, M., Braña, I., Calvo, E., Castelo-Branco, L., Colombo, I., de Azambuja, E., De Ruysscher, D., Dienstmann, R., Dingemans, A. M., Ekholm, M., Gallois, C., Golfinopoulos, V., Grande, E., Halabi, S. & Le Rhun, E. & 33 others, , May 2026, In: Annals of Oncology. 37, 5, p. 608-623 16 p.Research output: Contribution to journal › Article › peer-review
-
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO)
Moser, S. S., Zer, A., Hejazi, A., Passwell, N., Hoshen, M., Virani, A., Sharmokh, S., Daaboul, N., Gazit, S. & Bar, J., 2026, (Accepted/In press) In: Expert Review of Anticancer Therapy.Research output: Contribution to journal › Article › peer-review
Open Access -
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
Tomasini, P., Juan-Vidal, O., Califano, R., Lin, C. C., Hulo, P., Dooms, C., Fang, J., Blasco, A., Kowalski, D., Salinas, J., Babu, G., Mun, T. L., Bearz, A., Surmont, V., Baldotto, C., Sharma, R., Arrieta, O., Stencel, K., Card, C. & Zer, A. & 12 others, , Mar 2026, In: Clinical Lung Cancer. 27, 2, p. 38-47 10 p.Research output: Contribution to journal › Article › peer-review